Top 20 Primary Care Drugs Approved in 2016
Primary care drugs were approved in nearly every month of 2016. This top-line slide show highlights 20 you should know about.
Type 2 diabetes - hepatitis B virus â inflammation â stroke â obesity â pain â allergy â hypertension â asthma â COPD - migraine â and more.
Soliqua and Xultophy combine insulin and a GLP-1 receptor agonist and were approved to treat type 2 diabetes.
Intrarosa is a vaginally administered steroid for postmenopausal women experiencing pain during sexual intercourse.
Vemlidy is approved to treat chronic hepatits B virus infection in adults with compensated liver disease.
Zinplava is a selective, fully human monoclonal antibody approved to reduce recurrent
clostridium difficile
infection in adults.
Amjevita and Erelzi are biosimlars to popular branded drugs that treat rheumatoid arthritis, psoriatic arthritis and other inflammatory disease.
Yosprala is a fixed-combination platelet aggregation inhibitor/PPI for patients at risk for gastric ulcers who require aspirin therapy for secondary prevention of CVD and stroke.
Lomaira is a sympathomimetic amine anorectic approved for short-term weight reduction in overweight or obese adults.
Troxyca ER is an abuse-deterrent extended release opioid approved to manage severe pain that requires daily, around-the-clock opioid treatment.
Flonase Sensimist is an OTC corticosteroid nasal spray approved to treat symptoms of seasonal and perennial allergies.
Qbrelis is an oral formulation of ACE inhibitor lisinopril approved to treat hypertension in adults and children aged ⥠6 years, heart failure, and acute MI in adults. Byvalson is a fixed-dose combination beta-blocker/ARB to treat hypertension.
Viekira XR and Epclusa are fixed-dose combination direct-acting antiviral agents approved to treat chronic hepatitis C infection in adults.
Xiidra is a lymphocyte function-associated antigen-1 antagonist for treating the signs and symptoms of dry eye disease.
Bevespi Aerosphere is a fixed combination LABA/anticholingergic approved for maintenance therapy in COPD. Cinquair is an IL-5 monoclonal antibody for adjunctive treatment of eosinophilic asthma.
Onzetra Xsail is an intranasal triptan (sumatriptan) for treating migraine without aura; Zembrace Sym Touch is a prefilled single-dose autoinjector (sumatriptan) to treat acute migraine, with or without aura.
New drugs for conditions treated in primary care received FDA approval in nearly every month of 2016. Scroll through the slides above for a top-line look at some of the significant approvals over the past 6 months and a few important ones from the first quarter of the year. SOURCESCenterWatch: 2016 FDA Approved Drugs Drugs.com: New Drug ApprovalsÂ